GENSCRIPT BIO (01548) shares climbed more than 4% in Hong Kong trading, reaching 25.92 Hong Kong dollars with a turnover of 757 million Hong Kong dollars as of press time, up 4.18%.

The company released its interim results for the six months ending June 30, 2026, reporting revenues of approximately 404 million US dollars on a comparable basis, a 27.3% increase year-over-year. Gross profit rose 48% to about 207 million US dollars, while adjusted net profit surged 203.3% to roughly 62.5 million US dollars.

During the reporting period, the life sciences division generated revenues of approximately 319 million US dollars, up 28.8% from the prior year, with adjusted operating profit jumping nearly 102.8% to about 94 million US dollars. The company attributed this growth to a structural increase in AI-driven drug discovery, which has fueled rising demand for integrated "gene-to-protein" solutions.

Notably, GENSCRIPT BIO's globally leading gene-to-protein platform now accounts for roughly 66% of life sciences segment revenue, solidifying its position as a key growth driver. The AIDD (AI-driven drug discovery)-related business doubled year-over-year, maintaining a rapid growth trajectory for the third consecutive half-year period. The company also highlighted that deepening collaborations with top global AI pharmaceutical firms are strengthening its competitive edge as a premier wet-lab validation platform, and it expects order revenues from AIDD to continue doubling in the future.